Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes


1Ludwig Institute for Cancer Research (London Branch), St. George's Hospital, Tooting, London SW17, 2Section of Medicine, and 3Department of Histopathology, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.

Summary: A series of 7 patients with granulocytic sarcoma is presented to illustrate its varied clinical picture. In particular, this condition may present with features which suggest a non-Hodgkin lymphoma. The diagnosis will only be made if a high index of suspicion is maintained and special histopathological methods are used. Granulocytic sarcoma should be treated like an acute myeloid leukaemia.

Introduction

Granulocytic sarcoma (chloroma) is a rare extramedullary tumour composed of primitive cells of the granulocytic series. It was first described by Burns in 1811 and the name chloroma was used by King in 1853 to emphasize the greenish colour often found in the tumour which fades on exposure to air.

The tumour occurs in a variety of clinical settings and is often difficult to diagnose. It is closely associated with acute myeloid leukaemia which may be present at the time of initial diagnosis of granulocytic sarcoma, or, less commonly, may develop later. When granulocytic sarcoma presents without evidence of acute antecedent or coexisting myeloid leukaemia the diagnosis may be overlooked.

The tumour is usually undifferentiated, making histological diagnosis difficult. However, certain techniques such as electron microscopy, the chloroacetate esterase (CAE) stain and the immunohistological demonstration of lysozyme, an enzyme known to occur in the primary granules of monocytes and myeloid cells, have been used to facilitate the diagnosis.

We describe 7 patients who have been seen at the Royal Marsden Hospital over the past 5 years. All of them presented diagnostic difficulty, and several were initially diagnosed as having non-Hodgkin lymphomas. They were only diagnosed by special histological methods or when acute myeloid leukaemia subsequently developed. We have not included patients presenting with acute myeloid leukaemia in whom soft tissue tumours (granulocytic sarcomas) were found incidentally and presented no diagnostic or management problems.

Patients

The details of the 7 patients are summarized in Table I. Cases 3, 6 and 7 presented with syndromes clinically indistinguishable from non-Hodgkin lymphoma. Only one of the patients (case no. 7) had had a bone marrow examination done before attending the Royal Marsden Hospital and all of them had symptoms relating to their mass for between 2-7 months before the aspiration. In 3 cases (nos. 3, 4, 5) the finding of acute myeloid leukaemia prompted re-examination of the biopsy material with the use of the definitive CAE stain (Figure 1).

Although all the patients eventually died of their disease, patients who were treated with the regimens used for acute myeloid leukaemia had complete remissions lasting from 2-16 months (Table II). Those who were initially thought to have lymphomas and were treated as such did not have a period of remission.

Discussion

These cases illustrate the diverse presentations of granulocytic sarcoma and the extent to which they may mimic non-Hodgkin lymphoma. We cannot be certain that the outcome would have been better if all patients had been diagnosed immediately and treated with therapy appropriate for acute myeloid leukaemia. The survival of patients with granulocytic sarcoma is reported to be similar to that of patients with acute myeloid leukaemia in the absence of a tumour mass, and various reports of granulocytic sarcoma preceding acute leukaemia suggest that it is of prognostic importance to recognize the condition and start systemic treatment with appropriate leukaemia.

Correspondence: P.J. Selby, M.D., M.R.C.P.
Accepted: 25 November 1986

© The Fellowship of Postgraduate Medicine, 1987
### Table I  Clinical, pathological and survival characteristics of patients

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (years)</th>
<th>Presenting syndrome</th>
<th>Initial histological diagnosis at RMH</th>
<th>Chloroacetate esterase stain on initial biopsy</th>
<th>Diagnosis of granulocytic sarcoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>38 F</td>
<td>L. submandibular and parasternal mass</td>
<td>Granulocytic sarcoma</td>
<td>Not done</td>
<td>AML on 1st marrow at RMH</td>
</tr>
<tr>
<td>2</td>
<td>53 M</td>
<td>Mass R. upper arm and mass at porta hepatitis</td>
<td>Granulocytic sarcoma</td>
<td>+</td>
<td>CAE</td>
</tr>
<tr>
<td>3</td>
<td>25 M</td>
<td>Small bowel tumour causing obstruction</td>
<td>Poorly differentiated lymphocytic lymphoma</td>
<td>+</td>
<td>CAE and AML one month after diagnosis</td>
</tr>
<tr>
<td>4</td>
<td>38 M</td>
<td>Bone pain with deposits in ribs</td>
<td>Anaplastic carcinoma</td>
<td>+</td>
<td>CAE and AML two months after diagnosis</td>
</tr>
<tr>
<td>5</td>
<td>8 M</td>
<td>Bilateral orbital infiltration</td>
<td>Granulocytic sarcoma</td>
<td>+</td>
<td>CAE and AML on 1st marrow at RMH</td>
</tr>
<tr>
<td>6</td>
<td>26 M</td>
<td>Supraclavicular and axillary nodes Mediastinal mass</td>
<td>Diffuse histiocytic lymphoma</td>
<td>Not done</td>
<td>AML three months after diagnosis</td>
</tr>
<tr>
<td>7</td>
<td>33 M</td>
<td>Flu-like illness L. supraclavicular nodes</td>
<td>Diffuse poorly differentiated lymphoma</td>
<td>—</td>
<td>AML 9 months after diagnosis</td>
</tr>
</tbody>
</table>

F = female  M = male  AML = acute myeloid leukaemia  CAE = chloroacetate esterase  L = left  R = right  RMH = Royal Marsden Hospital

### Table II  Treatment and outcome

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>First treatment</th>
<th>Initial outcome</th>
<th>Length of remission (months)</th>
<th>Subsequent treatment and outcome</th>
<th>(duration in months)</th>
<th>Survival presentation to death (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BF9</td>
<td>CR</td>
<td>16</td>
<td>(1) BF9 + BMT  CR</td>
<td>17</td>
<td>40</td>
</tr>
<tr>
<td>2</td>
<td>BF9</td>
<td>CR</td>
<td>2</td>
<td>(2) E.C + DXR  CR</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>3</td>
<td>BF9</td>
<td>CR</td>
<td>5</td>
<td>(1) DXR  CR</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>BF9</td>
<td>PR</td>
<td>Failed to attend for follow up</td>
<td>(2) High dose M  Death</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>5</td>
<td>CHOP</td>
<td>CR</td>
<td>5</td>
<td>Bone marrow transplant  Death – Graft versus host disease</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>CHOP</td>
<td>PD</td>
<td>—</td>
<td>Multiple drugs  PD and death</td>
<td></td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>CHOP</td>
<td>PD</td>
<td>—</td>
<td>Multiple drugs  PD and death</td>
<td></td>
<td>13</td>
</tr>
</tbody>
</table>

**BF9**  **CHOP**

Adriamycin  Daunorubicin  Vincristine  Prednisone  Cyclophosphamide  Melphanal  6-thioguanine (an AML regimen)  Adriamycin (a lymphoma regimen)  C = Cyclophosphamide  E = Etoposide  M = Melphanal  P = Prednisone  BMT = Bone marrow transplant  CR = Complete remission  PR = Partial remission  PD = Progressive disease  DXR = Radiotherapy

Downloaded from http://pmj.bmj.com/ on June 19, 2017 - Published by group.bmj.com
regimens if survival is to be increased.6,7,9,10

The clinical and pathological diagnosis of granulocytic sarcoma continues to be a problem. It is essential to bear this condition in mind when confronted by problematic 'undifferentiated tumours' existing in soft tissues, bone or parenchymal organs. Bone marrow examination must be made and biopsy material stained with CAE. In addition, when doubt exists about the diagnosis of non-Hodgkin lymphoma – particularly in cases which behave atypically, such as failure to remit on conventional chemotherapy – then the biopsy material should be re-examined for CAE positivity.

If a granulocytic sarcoma is diagnosed in the absence of leukaemia we suggest that treatment with an acute myeloid leukaemia regimen should be used and consideration be given to bone marrow transplantation in remission.

References

Granulocytic sarcoma: a diagnosis to be considered in unusual lymphoma syndromes.

doi: 10.1136/pgmj.63.740.447

Updated information and services can be found at:
http://pmj.bmj.com/content/63/740/447

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/